Global Cell Culture Market - 2022-2029

Global Cell Culture Market - 2022-2029

Market Overview

The Global Cell Culture Market is expected to grow at a high CAGR of 11.9% during the forecasting period (2022-2029).

Cell culture involves maintaining cells of multi-cellular organisms outside their original body under specific conditions. It is a major technique used in both molecular and cellular biology as it provides the best platform for studying the normal physiology and biochemistry of cells. This process is significantly important in vaccine development, screening, and diagnosis of a given disease/condition.

Market Dynamics

The global cell culture market growth is driven by the increase in the number of cancer research projects using cell culture, extensive usage of gene therapies, recent developments in novel vaccine therapies, growing usage, and diverse application of stem cells.

The increasing contact between humans and animals will drive the market growth

The increasing contact between humans and animals has increased the threat of new virus outbreaks. Influenza and COVID-19, for example, have proven unpredictable and recurring events that pose a significant economic and social burden. As of February 4, 2022, 386.55 million cases of COVID-19 were confirmed globally, including 5.71 million deaths, by the WHO. The increasing incidence of infectious diseases and the growing risk of pandemics are expected to drive vaccine demand worldwide. In the pharmaceutical industry, cell culture has become a prominent part of vaccine production.

The cell culture technology has been used to produce vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox. Cell-based flu vaccines have also been approved for use in the US and many European countries. Increasing awareness of the benefits of cell culture-based vaccines, coupled with the regulatory approval of several cell culture-based vaccines worldwide, are the major factors in the growth of the cell culture market during the forecast period.

The companies are also investing in the research and development of new technologies. For instance, in February 2020, Belgium Based CDMO Univercells received up to EUR 50 million in financings from Gamma Biosciences, a new investment platform supported by a leading global investment firm, KKR, focused on next-generation bioprocessing technologies for the production of advanced biologic therapies, including gene- and cell-based therapies.

The high cost of cell biology research will hamper the growth of the market

Cell biology involves extensive R&D on new therapies such as stem cell and gene therapies. The equipment, reagents, and other products associated with research must be of the highest quality to provide accurate results. Owing to the growing need to maintain high-quality standards (through the use of high-grade products) and comply with guidelines set up by regulatory bodies, the cost of cell biology research has increased considerably. As a result, various academic institutes and small-scale companies with limited budgets cannot afford to conduct cell biology research. This factor will hamper the growth of the market in the forecast period.

COVID-19 Impact Analysis

In the context of COVID-19, government organizations in various countries, research institutes, and many biotechs and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines/new therapeutics to overcome the current situation. Cell culture may serve as a potential platform for the development of novel vaccines for the treatment of COVID-19. Researchers working on related coronaviruses SARS and MERS are focusing on cell culture-based treatment approaches for the COVID-19 treatment and conducting research in developing vaccines based on cell cultures.

With the COVID-19 outbreak situation, the drug development process is at its peak, across the biotechnology industry. Several companies and research organizations are involved in developing coronavirus drugs/vaccines. For instance, Entos Pharmaceuticals, Roivant Sciences, Altimmune, Biopharma, etc., are involved in the drug development for treating the contagious coronavirus infection. Thus these factors are driving the growth of the market during the pandemic.

Segment Analysis

The drug screening & development segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Cell culture is an integral part of medical research and drug discovery. The two-dimensional (2D) culture has been the preferred method for many decades due to the ease with which cell monolayers can be induced to proliferate on planar surfaces. The cell culture industry has witnessed its evolution, and currently, there has been an emergence of 3D cell culture in the market. Drug development is a time-consuming and costly procedure that is finished in multiple stages, from target identification to lead discovery and optimization, preclinical validation, and clinical trials culminating in approval for clinical use. Cell-based high throughput screening (HTS) is currently being carried out on cultured cells propagated in two dimensions (2D) on plastic surfaces optimized for tissue culture. With the emergence of 3D cell culture, the process of HTS has become easier and more accurate.

Furthermore, various global regulatory groups have improved their support for gene and cell therapy, which is positive. There was a notion of an arms race between different regional bodies the United States, Europe, the United Kingdom, China, and Japan to a degree, and in various ways within different specialties. Recently, it appears that regulatory authorities have been more open and collaborative in recognizing the differences between cell and gene therapy and more established biopharma cancer treatments. They are willing to put in place the necessary regulatory mechanism to allow these drugs to reach the market and to monitor them in the future. Thus, these factors are driving the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global cell culture market

North America dominates the market for cell culture market owing to the growing demand for personalized medicine and the presence of key players in the market. Additionally, the United States government is supportive in terms of medical research as healthcare is one of the major priorities in the country. The Human Cancer Models Initiative was announced in 2016, which aimed to grow 1,000 new cell lines for scientists to study within three years. The initiative included the US National Cancer Institute (NCI) in Bethesda, Maryland, Cancer Research UK, the Welcome Trust Sanger Institute UK, and Hubrecht Organoid Technology of Utrecht in the Netherlands.

Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. However, the FDA has put several requirements in place for the production process due to the risk of contamination. Furthermore, in 2019, the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) released their first official policy document on the joint regulation of cell-cultured meat. ​With the rising focus on cell-based research, it is believed that there may be more technological advancements in the field, and this is likely to impact the US market in a positive manner in the forecast period.

Competitive Landscape

The cell culture market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Biospherix, Hi-Media Laboratories, Merck KgaA, Promocell GmbH, Sartorius AG, and Thermo Fisher Scientific, Danaher Corporation, Sekisui XenoTech LLC, Lonza Group, Agilent Technologies Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cell culture market globally. For instance, in March 2022, Thermo Fisher Scientific launched its new Gibco Human Plasma-like Medium (HPLM), the first type of cell culture medium that mimics the metabolic profile of human plasma and is designed to provide researchers with a realistic view of cell growth within the human body.

Bayer AG

Overview:

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Product Portfolio:

Roller Bottles and Accessories: Thermo Scientific Nunc PETG Roller Bottles are molded in shatter-resistant PETG and are available on both smooth and pleated surfaces. Growth areas range from 1,050 cm² to 4,200 cm² help enable increased cell expansion and product yield without investing in additional equipment or increased labor. PETG can be frozen to –40°C for freeze-thaw release protocols.

Why Purchase the Report?

Visualize the composition of the global cell culture market segmentation by product, application, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global cell culture market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global cell culture market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cell culture market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 189 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers